Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: France,Belgium,Australia,Czech Republic,Argentina,Croatia,Italy,Germany,Taiwan, Province of China - Phase: complete
nct
Update Il y a 5 ans
Satavaptan Dose-Ranging Study in the Prevention of Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone. The secondary objective was to determine the tolerability of different fixed doses of SR121463B in cirrhotic ascites, over a 12-week treatment period. This SPA study is followed by a single-blind, placebo-controlled, 40 weeks long-term safety extension (ExSPA). The first extension is followed by another long-term study (PASCCAL-1).
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Italy
,
Spain
,
Taiwan, Province of China
,
organs
None
Specialty
None
Closed trial
More information
1